https://orphanika.org/news/fda-approves-fayuvi-sanfilippo-syndrome-type-a/2026-09-23T21:32:20+00:00https://orphanika.org/news/fda-approves-isembyld-apitegromab-mstn-spinal-muscular-atrophy/2026-09-23T22:18:20+00:00https://orphanika.org/news/fda-approves-mimrylo-rusfertide-polycythemia-vera/2026-09-23T22:41:16+00:00https://orphanika.org/news/fda-approves-lyrfigtu-cholangiocarcinoma-fgfr2/2026-09-25T20:15:09+00:00https://orphanika.org/news/fda-approves-atebrioz-zilurgisertib-fop-treatment/2026-09-25T23:19:44+00:00https://orphanika.org/news/fda-approves-zanvastro-zilganersen-alexander-disease/2026-09-26T20:58:45+00:00https://orphanika.org/news/amgen-dazodalibep-phase3-sjogrens-disease-positive/2026-09-27T13:10:37+00:00https://orphanika.org/news/fda-approves-lisraya-brepocitinib-dermatomyositis/2026-09-29T06:49:14+00:00https://orphanika.org/news/fda-accelerated-approval-genglycos-gsdia-gene-therapy/2026-09-30T09:52:08+00:00https://orphanika.org/news/fda-approves-emcitate-tiratricol-mct8-deficiency-2/2026-10-01T07:58:03+00:00https://orphanika.org/news/allopurinol-first-orphan-drug-marfan-syndrome/2026-10-02T19:36:38+00:00https://orphanika.org/news/fda-approves-gomekli-mirdametinib-nf1-pn-treatment/2026-10-03T11:57:08+00:00https://orphanika.org/news/merck-tulisokibart-phase2b-hs-win/2026-10-04T12:05:40+00:00https://orphanika.org/news/what-ctexli-chenodiol-brings-to-ctx-metabolic-correction/2026-10-05T11:13:20+00:00https://orphanika.org/news/fda-approves-besremi-ropeginterferon-alfa-2b-njft-essential-throm/2026-10-06T15:48:54+00:00https://orphanika.org/news/fda-approves-trutakna-atacicept-for-primary-iga-nephropathy/2026-10-07T08:01:32+00:00https://orphanika.org/news/what-levacetylleucine-brings-ataxia-telangiectasia/2026-10-09T18:12:32+00:00